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Dermato®bromas have an increased brownish color
due to hyperpigmentation of the overlying skin. To
determine paracrine factors involved in the epider-
mal hyperpigmentation, we have studied the expres-
sion of cytokines in lesional and nonlesional
dermato®broma skin at the transcriptional and
protein levels using reverse transcription polymerase
chain reaction and immunohistochemistry, respect-
ively. The number of tyrosinase immuno-positive
melanocytes in the pigmented dermato®broma epi-
dermis is signi®cantly increased (2-fold) compared
with nonlesional normal epidermis. Reverse tran-
scription polymerase chain reaction analysis of
mRNAs encoding stem cell factor and hepatocyte
growth factor demonstrated that there is an accentu-
ated expression of stem cell factor and hepatocyte
growth factor transcripts in the lesional dermato®-
broma dermis compared with the nonlesional der-
mis, although there is no difference in their
expression between the lesional and nonlesional epi-
dermis. In contrast, mRNA transcripts encoding
endothelin-1, growth-related oncogene a, and basic
®broblast growth factor are not increased in lesional
epidermis or in dermis relative to nonlesional skin.
In parallel, immunohistochemical analysis using anti-
bodies to stem cell factor and hepatocyte growth fac-
tor reveal a marked immunostaining in growing
®broblastic tumor cells in the dermato®broma
lesions with no detectable staining in the nonlesional
dermis, but there is no difference in their immunos-
taining between the lesional and nonlesional epider-
mis. Interestingly, and consistent with the increased
expression of stem cell factor in lesional dermato®-
broma dermis, toluidine blue staining in the dermis
revealed a 5-fold increase in the number of mast
cells, an indication of their longevity or accumula-
tion induced by stem cell factor. These ®ndings sug-
gest an important role of ®broblastic tumor cell-
derived stem cell factor in the mechanism involved
in the hyperpigmentation of the dermato®broma
epidermis. Key words: cytokines/®broblasts/mast cell/
melanocytes. J Invest Dermatol 117:627±633, 2001
D
ermato®broma (DF) is a benign dermal tumor of
®broblast-like cells (Heenan, 1997); it is also known
as histiocytoma, benign ®brous histiocytoma, and
sclerosing hemangioma. It has been reported that
some cases of multiple DF are associated with
autoimmune diseases such as systemic lupus erythematosus
(Newman and Walter, 1973; Lin, 1986). In lesional DF skin, there
is an abnormal accumulation of proliferating ®broblast-like cells and
histiocytes surrounded by mature collagen and by increased
capillaries. Of particular interest is the fact that the epidermis
overlying the DF tumor is markedly hyperpigmented with a slight
acanthosis (Heenan, 1997), although the mechanism behind the
pathogenesis of the epidermal hyperpigmentation remains to be
clari®ed. It has been well established that typical epidermal
pigmentation is accompanied by an increased number of
melanocytes and by an enhanced melanization associated with
increases in melanocyte proliferation and expression of tyrosinase,
respectively.
In ultraviolet (UV) induced epidermal pigmentation, the
paracrine cytokine linkage between keratinocytes and melanocytes
within the epidermis is documented to play an essential role in
accentuating the proliferation and melanogenesis of melanocytes
(Imokawa et al, 1992, 1995, 1996a, b). Those cytokines include
endothelins (ET) and granulocyte±macrophage colony stimulating
factor (GM-CSF), which are involved in UVB- and UVA-induced
epidermal pigmentation. Furthermore, in non-UV associated
pigmentary disorders, such as seborrheic keratosis (Teraki et al,
1996) and lentigo senilis (Kadono et al, 2001), a similar paracrine
cytokine such as ET is an intrinsic melanogenic factor responsible
for stimulating proliferation and melanogenesis by melanocytes. It
has also been reported that important cytokines in the paracrine
linkage between ®broblasts and melanocytes in cutaneous human
pigmentation include stem cell factor (SCF) and hepatocyte growth
factor (HGF) (Imokawa et al, 1998b). As SCF and HGF derived
from human ®broblasts regulate cutaneous pigmentation, those
cytokines might be derived from ®broblastic tumor cells in DF and
may be involved in the epidermal hyperpigmentation.
To test this hypothesis, we investigated gene expression and
protein levels of ®broblastic tumor cell derived melanogenic factors
such as SCF, HGF, basic ®broblast growth factor (bFGF), growth-
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related oncogene a (GRO-a), and ET-1 in DF using reverse
transcription polymerase chain reaction (RT-PCR) and immuno-
histochemistry. Here we report that the mechanism of epidermal
hyperpigmentation in DF involves SCF and HGF, which are
secreted in abundance by the ®broblastic tumor cells and which
induce melanogenic stimulation in the adjacent epidermal
melanocytes.
MATERIALS AND METHODS
Materials Streptavidin±biotin immunoperoxidase staining systems were
obtained from Shandon-Lipshaw (Pennsylvania).
Antibodies Polyclonal antibodies speci®c for human SCF (Yamataka
et al, 1998), ET-1, HGF (Takanami et al, 1996), bFGF, and GRO-a
were purchased from Immuno Biological Laboratories (IBL, Gunma,
Japan). The monoclonal antibody to human tyrosinase was obtained
from Biochemical Industrial (Tokyo, Japan).
Skin samples Skin biopsy specimens were obtained from DF lesional
and perilesional skin (n = 13, four Japanese males and nine Japanese
females, mean age 33.7 y). The representative clinical appearance of DF
and the skin architecture of these lesions are shown in Fig 1(A). All DF
studied had dark brownish color on the overlying skin. The sites of skin
excisions were the abdomen, the extremities, and the buttocks, which
are generally sun-protected skin areas, and there were no symptoms of
sun exposure when the biopsies were taken. The main portion of each
specimen was subjected to routine histopathologic examination. The
remaining sample specimens were embedded in Tissue-Tek OCT
compound (Miles, Indiana), snap-frozen in liquid nitrogen, and then
stored at ±80°C until use.
Immunohistochemistry Cryostat sections (4 mm thick) were air-
dried, ®xed in cold acetone, washed in 0.01 M phosphate-buffered saline
pH 7.2 (PBS+), and then incubated in 3% H2O2 for 5 min at room
temperature. After further washing in PBS(+), sections were incubated
with the protein blocking agent for 20 min at room temperature. After
washing again in PBS(+), the sections were incubated overnight at 4°C
in PBS(+) containing antibodies (1:50) to SCF, HGF, bFGF, ET-1,
GRO-a, or tyrosinase. After further washing in PBS(+), the sections
were incubated for 30 min at room temperature with rabbit IgG
antibody. The sections were again washed in PBS(+) and were then
incubated for 30 min at room temperature with standard Omnitags
streptavidin-peroxidase. The reaction was developed with
aminoethylcarbazole (AEC); the sections were incubated for 10±15 min
at room temperature with Omnitags plus/HRP kit consisting of two
drops of sodium acetate buffer, two drops of AEC chromogen
concentrate, and two drops of 3% H2O2 in distilled water. The sections
were then washed in PBS(+) and stained with hematoxylin±eosin.
RT-PCR Biopsy specimens were obtained from the skin as detailed
above and the adipose tissue was removed with a surgical knife. The
epidermis and the dermis of each specimen was then separated by
heating for 3 min at 60°C. The residue of separated tissue was examined
after periodic acid±Schiff (PAS) staining to con®rm that the separation
took place within the epidermis, leaving no dermal components on the
epidermal sheet. Total cellular RNA was then extracted from the
epidermis and from the dermis using the acid guanidinium phenol
chloroform method with only a single precipitation. The RNA was
quanti®ed by measuring the optical density at 260 nm, and about 1 mg
of total RNA was obtained from each tissue sample. To synthesize
oligo(dT16)-primed cDNA, total RNA was heated to 65°C for 3 min,
and then chilled on ice. Reverse transcription was performed in 20 ml
reaction mixtures containing 2 ml 10 3 PCR buffer II: 4 ml MgCl2
(25 mM), 1 ml oligo(dT16) (2.5 mM), 8 ml deoxynucleotides (2.5 mM
each), 1 ml RNase inhibitor (1 U per ml), 1 ml Moloney murine
leukemia virus reverse transcriptase (2.5 U per ml), and 3 ml RNA
Figure 1. Clinical and histological characteristics of DF. (A) (a)
Clinical manifestation of DF. A slightly raised, hard brownish nodule is
seen on the thigh. (b) Hematoxylin and eosin section of DF, 333; an
irregularly demarcated tumor is located in the dermis. The tumor is
composed of ®broblasts, histiocytes, and mature collagen ®bers. The
epidermis overlying the tumor shows basal hyperpigmentation and slight
acanthosis. (B) Immunohistochemistry of DF with tyrosinase antibodies:
(a) lesional skin of DF, 380; (b) perilesional skin, 380. (C) The
increased number of tyrosinase-positive melanocytes in DF: (a) the
number per millimeter length; (b) the number per 100 basal cells. Scale
bar: (A) 90 mm; (B) 220 mm.
Table I. Nucleotide sequences for 5¢ and 3¢ primers
Endothelin-1 365 bp
5¢ primer 5¢-TTCCCACAAAGGCAACAGACCG-3¢
3¢ primer 5¢-GACAGGCCCCGAAGTCTGTCA-3¢
bFGF 243 bp
5¢ primer 5¢-GGAGTGTGTGCTAACCGTTACCTGGCTATG-3¢
3¢ primer 5¢-TCAGCTCTTAGCAGACATTGGAAGAAAAAG-3¢
GRO-a 250 bp
5¢ primer 5¢-GGATCCAAGCAAATGGCCAATGAG-3¢
3¢ primer 5¢-TGTTCTAAGCCAGAAACACTG-3¢
SCF 351 bp
5¢ primer 5¢-GATGTTTTGCCAAGTCATTGTTGG-3¢
3¢ primer 5¢-ACTGACTCTGGAATCTTTCTCAGG-3¢
HGF 396 bp
5¢ primer 5¢-GTTATCGTGGGAATGGCAA-3¢
3¢ primer 5¢-ATGATCCTCCGCAGATATG-3¢
GAPDH 516 bp
5¢ primer 5¢-GAAGGTGAAGGTCGGAGTCAACG-3¢
3¢ primer 5¢-AGTCCTTCCACGATACCAAAGTTG-3¢
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(100 ng in DEPC-treated water). Reaction mixtures were incubated at
42°C for 60 min and at 52°C for 30 min, and then heated to 99°C for
5 min to inactivate the reverse transcriptase. For PCR ampli®cation, 3 ml
of each cDNA reaction mixture was added to an 80 ml PCR mixture
containing 4 ml MgCl2 (2 mM), 8 ml 10 3 PCR buffer II, 5 ml 3¢ and 5¢
primers (10 mM each), and 1 ml Taq polymerase (Cetus). Reaction
mixtures were ampli®ed using a Perkin-Elmer/Cetus thermal cycler. The
PCR cycle conditions were: melting for 1 min at 95°C, annealing for
1 min at 60°C, and extension for 2 min at 72°C. Reaction products
(1.5 ml) were resolved on 1.5% agarose gels and were visualized by
ethidium bromide staining. The sequences of the 3¢ and 5¢ primer pairs
used in this study are shown in Table I. As negative controls, we
conducted PCR without reverse transcriptase and con®rmed that there
was no ampli®cation of the transcripts. To quantitate the expression of
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the transcripts, the intensities of PCR bands were measured by
densitometry and are expressed as relative intensities to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Statistics The levels of signi®cance of differences were calculated by
the Student t test.
RESULTS
Melanocytes proliferate in DF epidermis Immunostaining of
epidermal melanocytes with a tyrosinase antibody (Fig 1B) reveals
that there is an increase in tyrosinase-positive melanocytes in
lesional DF epidermis compared with nonlesional epidermis.
Quantitation of tyrosinase-positive melanocytes per millimeter
length of the horizontal interface between the epidermis and
dermis, or per 100 basal cells, demonstrates that the number of
melanocytes signi®cantly increases in the lesional DF epidermis
compared with the nonlesional epidermis (Fig 1C).
RT-PCR analysis of melanogenic cytokines We measured
the gene expression of melanogenic cytokines (SCF, HGF, bFGF,
GRO-a, and ET-1) in nonlesional and in lesional DF epidermis
and dermis. In the epidermis, three (Nos. 1, 2, and 5) out of six
cases had a slight expression of SCF transcript, but the levels of
distinct expression found in two (Nos. 1 and 2) of the other three
cases did not differ between the nonlesional and the lesional DF
epidermis (Fig 2A). In contrast, the gene expression of SCF in the
lesional dermis was de®nitely increased (average 1.68-fold, n = 6)
compared with the nonlesional controls in ®ve out of the six cases
(Fig 2A). Using RT-PCR analysis, there was no expression of
HGF mRNA either in the nonlesional or in the lesional DF
epidermis under our experimental conditions, but in the dermis
HGF gene expression was markedly increased (average 2.27-fold,
n = 6) relative to the nonlesional dermis in all six cases (Fig 2B).
On the other hand, the results of RT-PCR analysis for bFGF,
GRO-a, and ET-1 differed from those for SCF and HGF. There
was no difference in bFGF expression in the epidermis or dermis
(average 0.84-fold, n = 6) in lesional and nonlesional skin
(Fig 2C). GRO-a was also similar in lesional and nonlesional
epidermis and dermis (average 0.79-fold, n = 6), except for
possibly slightly decreased expression in the epidermis in some
lesions (Fig 2D). The results of RT-PCR analysis of ET-1 mRNA
showed similar levels in the nonlesional and the lesional DF
epidermis and dermis (average 0.95-fold, n = 6) (Fig 2E).
Immunohistochemistry Keratinocytes stained positively for
SCF, HGF, bFGF, GRO-a, and ET-1 in the nonlesional and
the lesional DF epidermis (Fig 3). In addition, dermal blood
vessels, several ducts, glands, and hair follicles were also stained.
Although positive staining for these ®ve cytokines was con®ned to
®broblastic tumor cells in the lesional dermis, there was negative or
poor staining for SCF or HGF in normal ®broblasts in the
nonlesional dermis (Fig 3A, B). It is clear that levels of positive
staining for bFGF, GRO-a, and ET-1 in the nonlesional DF
®broblasts are similar to those found in individual cells of the
lesional tumor (Fig 3C±E). Consistent with the elevated level of
SCF in the dermis, there was an increased number of mast cells
surrounding the tumor measured using toluidine blue staining
(Fig 4A). In the DF tumor lesion, there was about a 5-fold increase
in the number of mast cells compared with those in the normal
dermis (Fig 4B).
DISCUSSION
In epidermal pigmentary disorders, the paracrine network of
cytokines plays an essential role in stimulating epidermal melano-
cytes following their secretion by nonmelanocytic cells in the skin
(Teraki et al, 1996; Imokawa et al, 1997; Kadono et al, 2001). In
UVB-induced pigmentation, ET-1 and membrane-bound SCF
have been associated as keratinocyte-derived cytokines that stimu-
late melanogenesis in epidermal melanocytes (Imokawa et al, 1992,
1995; Hachiya et al, 2001). In contrast, in UVA-induced pigment-
ation, GM-CSF has been identi®ed as a keratinocyte-derived
melanogenic cytokine (Imokawa et al, 1996b). GRO-a has been
found to be associated with allergy-induced hyperpigmentation
when it is secreted by epidermal cells in the elicitation phase, after
which it stimulates adjacent melanocytes, leading to hyperpigment-
ation (Imokawa et al, 1998a). ET-1 has also been involved in the
mechanism of hyperpigmentation in the epidermis of lentigo senilis
(Kadono et al, 2001) and seborrheic keratosis (Teraki et al, 1996).
As for cytokines or growth factors other than ET that are involved
with hyperpigmentation, bFGF (Halaban et al, 1988) or a-
melanocyte-stimulating hormone (a-MSH) (Chakraborty et al,
1996) are also believed to be involved in UVB-induced pigment-
ation because they can stimulate the proliferation and/or
melanogenesis of cultured human melanocytes and because UVB
irradiation causes keratinocytes to produce bFGF (Halaban et al,
1988) or to release a-MSH into the medium (Schauer et al, 1994;
Chakraborty et al, 1996). Whether bFGF or a-MSH is a
constitutive mitogen or melanogen for human melanocytes in
UVB-induced pigmentation, however, remains to be further
clari®ed because of the lack of a secretory form of the former
produced by human keratinocytes and the weak mitogenic effect of
the latter (Abdel-Malek et al, 1995). In addition, there is no
evidence that antibodies to a-MSH can abrogate the stimulation of
proliferation and melanization in cultured human melanocytes
elicited by conditioned medium obtained from UVB-exposed
keratinocytes. Further, the requirements of other growth factors
such as bFGF (Abdel-Malek et al, 1995) or c-AMP raising factors
(Halaban et al, 1988) for the stimulation of melanocytes by a-MSH
or bFGF, respectively, minimizes their paracrine role in UVB-
induced pigmentation.
Figure 2. RT-PCR analysis of cytokine or chemokine transcripts
in the epidermis of DF and perilesional skin. (a) Fluorogram; (b)
densitometric analysis for the expression in dermis. (A) SCF; (B) HGF;
(C) bFGF; (D) GRO-a; (E) ET-1; n = 6. The intensities of each PCR
band are expressed as relative intensities to GAPDH. NL, the epidermis
and the dermis of DF perilesional skin; L, the epidermis and the dermis
of DF lesional skin; *p < 0.05.
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Although intrinsic cytokines associated with stimulation of
melanogenesis in various pigmentary disorders have not been
fully identi®ed, available evidence reveals that paracrine cytokines
interacting between epidermal melanocytes and nonmelanocytic
cells in the skin play a central role in epidermal hyperpigmentation.
The characteristic features of DF, including ®broblastic tumors in
the dermis and hyperpigmentation in the overlying epidermis,
allow us to speculate that paracrine cytokines produced by highly
proliferative ®broblast-like cells in the dermis might be primarily
responsible for the melanogenic stimulation of melanocytes in the
epidermis. In this connection, we have already found that
conditioned culture medium from proliferating human ®broblasts
has a potent ability to stimulate the proliferation of human
melanocytes in culture (Imokawa et al, 1996a; 1998b). Those
stimulatory activities were associated with SCF and HGF, which
are exclusively secreted in abundance by human ®broblasts derived
from aged persons.
Although there is little evidence for their paracrine role among
skin cells, SCF and HGF have also been implicated as mitogens for
human melanocytes in vitro and in vivo (Matsumoto et al, 1991;
Grichnik et al, 1995; Imokawa et al, 1996a, 2000). Treatment with
HGF at a concentration of 10 nM has been reported to stimulate
the proliferation of cultured human melanocytes (Matsumoto et al,
1991). Using an in vivo injection protocol, Grichnik et al (1995) and
Costa et al (1996) demonstrated a potent capacity of SCF to induce
hyperpigmentation in the epidermis, which was accompanied by an
increased proliferation of epidermal melanocytes. Consistent with
its stimulatory potential, as SCF is also known as mast cell growth
factor, increases in the numbers of mast cells and their degranula-
tion were also observed concomitant with melanocyte activation.
Figure 3. Immunohistochemistry with anti-
body to cytokines or chemokines in DF
lesional skin. (A) SCF: (a) low magni®cation,
311; (b) lesional area, 395; (c) perilesional area,
395. (B) HGF: (a) low magni®cation, 313; (b)
lesional area, 390; (c) perilesional area, 395. (C)
bFGF: (a) low magni®cation, 313; (b) lesional
area, 390; (c) perilesional area, 390. (D) GRO-
a: (a) low magni®cation, 318; (b) lesional area,
390; (c) perilesional area, 390. (E) ET-1: (a) low
magni®cation, 318; (b) lesional area, 390; (c)
perilesional area, 390. Scale bar: (A,a) 30 mm;
(A,b,c) 260 mm; (B,a) 35 mm; (B,b) 250 mm; (B,c)
260 mm; (C,a) 35 mm; (C,b,c) 250 mm; (D,a)
50 mm; (D,b,c) 250 mm; (E,a) 50 mm; (E,b,c)
250 mm.
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Thus, based upon the available evidence on the stimulatory effects
of several skin-cell-derived cytokines or chemokines on human
melanocytes, it is most likely that SCF or HGF derived from the
®broblastic tumors is responsible for the stimulation of epidermal
melanocytes, which leads to the hyperpigmentation restricted to
the epidermis overlying the ®broblastic tumors in DF. There are
different explanations, however, about the nature of the prolifer-
ating cells in the DF dermis as to whether the tumor cells are
derived from ®broblasts, histiocytes, or dermal dendrocytes
(Heenan, 1997).
This study demonstrates that, despite the lack of a signi®cant
difference in the expression of SCF and HGF transcripts in lesional
and nonlesional DF epidermis, there is an increased expression of
these transcripts in the lesional DF dermis relative to the
nonlesional dermis. In contrast, transcripts of other melanogenic
cytokines, such as GRO-a, bFGF, and ET-1, are expressed
similarly in lesional and nonlesional DF dermis and epidermis.
Because the gene expression is essentially expressed per cell (as
standardized by GAPDH), the increased expressions of SCF and
HGF transcripts imply that cells of the ®broblastic DF tumors
produce more of these proteins than do ®broblasts in the
nonlesional dermis. In support of this, immunostaining with SCF
or HGF antibodies in ®broblasts of the nonlesional DF dermis was
substantially negative, indicating that nonproliferating normal
®broblasts produce insigni®cant amounts of SCF or HGF. Based
upon this assumption, it is conceivable that there are copious
amounts of SCF and HGF secreted throughout the lesional DF
dermis, being suf®cient to reach and activate melanocytes in the
overlying epidermis. In contrast, the other melanogenic cytokines
tested (including GRO-a, bFGF, and ET-1) might also be secreted
by ®broblastic tumors, but at concentrations insuf®cient to contact
and activate melanocytes. The protein expression of SCF and HGF,
as evidenced by immunohistochemistry, is markedly elevated in the
lesional DF dermis compared with the nonlesional dermis, whereas
for the other melanogenic cytokines tested the transcripts and
protein levels of GRO-a, bFGF, and ET-1 are expressed at similar
levels between the lesional and nonlesional DF dermis and
epidermis. Taken together, our evidence suggests that, in the
lesional DF dermis, SCF and HGF are selectively produced and
secreted by ®broblastic tumors at concentrations suf®cient to
activate melanocytes located in the adjacent epidermis, which
results in the hyperpigmentation of the overlying skin.
Although there may be other possible explanations as to how
melanocytes in the overlying epidermis are activated in DF, the
ligand speci®city against different types of cells would help in
understanding the results of this study. Thus the fact that, in
addition to the increased numbers of activated melanocytes in the
overlying epidermis, the number of mast cells located beneath the
epidermis is increased 5-fold over that in the nonlesional skin
supports the suggestion that at least SCF is secreted in a soluble and
diffusible form by ®broblastic tumors at concentrations capable of
directly in¯uencing mast cells to increase their number. This
strongly suggests that at least soluble SCF plays an important role in
the epidermal hyperpigmentation of DF.
A similar type of epidermal hyperpigmentation associated with
SCF has been reported in mastocytosis in which the abnormal and
excessive conversion of the membrane-bound to the soluble form
of SCF in the epidermis plays an essential role in stimulating
epidermal melanocytes and proliferating dermal mast cells, respect-
ively (Longley et al, 1993). Thus, it is conceivable that the
threshold concentrations of SCF needed to stimulate melanocytes
and mast cells are similar. If mast cells are activated beneath the
epidermis by SCF, it seems reasonable to assume that melanocytes
are also activated by the same SCF as SCF is also known as mast cell
growth factor. Our ®nding that the numbers of mast cells are
increased 5-fold in DF skin compared with nonlesional skin may be
an interesting indication that the stimulated status of epidermal
melanocytes in DF can be ascribed to the action of SCF, which is
largely secreted as a soluble isoform by ®broblastic tumors but not
by lesional epidermal cells, as supported by the signi®cant increase
in SCF gene and protein expression in the lesional dermis but not
in the lesional epidermis compared with each nonlesional control.
This is concluded because of the existence of soluble SCF, which is
released into the medium by cultured human ®broblasts at a level
detectable by enzyme-linked immunosorbent assay, but not by
cultured human keratinocytes (Imokawa, 1996), and which diffuses
to the nearby epidermis. Thus, it is unlikely that the expression of
soluble SCF in the lesional epidermis is stimulated by unknown
factors derived from ®broblastic tumor, which results in the
stimulation of melanocytes and mast cells as seen for mastocytosis.
Unfortunately, as HGF is known just as a stimulator for hepatocytes
and melanocytes (Matsumoto et al, 1991) and as there are no other
types of skin cells that are known to respond to HGF, it is dif®cult
to de®ne the role of HGF in the hyperpigmentation seen in DF.
Figure 4. Population of mast cells in the
dermis of DF. (A) Histochemistry of DF with
toluidine blue staining (Nissl modi®ed stain): (a)
lesional skin, 3125; (b) perilesional skin, 3125.
(B) The increased number of metachromatically
stained mast cells in DF. Scale bar: 35 mm.
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The high expression of HGF in the dermis at both the gene and the
protein levels, however, would support a distinct role for HGF in
stimulating epidermal melanocytes in DF.
In conclusion, when taken together, the above ®ndings support
the pathogenic mechanism of DF in which the proliferating
®broblast-like cells have a potent ability to secrete SCF and HGF,
which then diffuse toward the epidermis. This would result in the
stimulation of melanocytes located at the basal layer of the
epidermis, which would lead in turn to hyperpigmentation limited
to the overlying epidermis, presumably accompanied by a
concomitant accumulation of mast cells.
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